Show simple item record

Olaparib (O) plus ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial

dc.contributor.authorLukashchuk, N.en
dc.contributor.authorPunie, K.en
dc.contributor.authorNowecki, Z.en
dc.contributor.authorIm, S. A.en
dc.contributor.authorArmstrong, Anne Cen
dc.contributor.authorJacot, W.en
dc.contributor.authorKim, J. H.en
dc.contributor.authorWebster, M. A.en
dc.contributor.authorBalmaña, J.en
dc.contributor.authorDelaloge, S.en
dc.contributor.authorCasson, E.en
dc.contributor.authorLoembe, B.en
dc.contributor.authorDean, E.en
dc.contributor.authorArmenia, J.en
dc.contributor.authorTutt, A. N. J.en
dc.date.accessioned2023-10-25T08:48:32Z
dc.date.available2023-10-25T08:48:32Z
dc.date.issued2023en
dc.identifier.citationLukashchuk N, Punie K, Nowecki Z, Im SA, Armstrong AC, Jacot W, et al. Olaparib (O) plus ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trial. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772000197.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.1087en
dc.identifier.urihttp://hdl.handle.net/10541/626634
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.1087en
dc.titleOlaparib (O) plus ceralasertib (C) in patients (pts) with metastatic triple-negative breast cancer (mTNBC): Translational analysis of the VIOLETTE trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentAstraZeneca, Cambridgeen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record